middle.news
OncoSil Boosts German Hospital Access by 43% for Pancreatic Cancer Device
8:37am on Tuesday 4th of February, 2025 AEDT
•
Medical
Read Story
OncoSil Boosts German Hospital Access by 43% for Pancreatic Cancer Device
8:37am on Tuesday 4th of February, 2025 AEDT
Key Points
120 German hospitals authorized to negotiate OncoSil™ device funding under NUB program
43% increase in hospital participation compared to 2024
German Ministry of Health approval and Coverage with Evidence Development Study Directive published
OncoSil™ device recognized for treating locally advanced unresectable pancreatic cancer
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Oncosil Medical (ASX:OSL)
OPEN ARTICLE